Injury and repair mechanisms in ischemic stroke: Considerations for the development of novel neurotherapeutics

Current Opinion in Investigational Drugs

Volumn 10, Issue 7, 2009, Pages 644-654

  Candelario Jalil, Eduardo ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Neuroinflammation; Neuroprotection; Neurorepair; Neurovascular unit; Thrombolysis

Indexed keywords

ALTEPLASE; ATORVASTATIN; AX 200; CAFFEINOL; CALCIUM; CASPASE 3; CASPASE 8; CITICOLINE; DISUFENTON SODIUM; DR 2313; ERYTHROPOIETIN; FIBRINOLYTIC AGENT; FR 247304; GELATINASE B; GLUTAMATE RECEPTOR ANTAGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN ALBUMIN; INO 1001; LU AA24493; MAGNESIUM SULFATE; MEVINOLIN; MINOCYCLINE; NEU 2000; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMESULIDE; NORPHENAZONE; NTX 265; PROTEIN BCL 2; STROMELYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AGITATION; APOPTOSIS; BLEEDING; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXCITOTOXICITY; FIBRINOLYTIC THERAPY; HALLUCINATION; HUMAN; INFLAMMATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PROGNOSIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; NEUROGENIC INFLAMMATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RECEPTORS, GLUTAMATE; REPERFUSION; STROKE;

EID: 68249115320     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics - 2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. (2009) 119(3):e21-e181.
2. Heart Disease and Stroke Statistics: Our guide to current statistics and the supplement to our heart and stroke facts:American Heart Association, Dallas, TX, USA (2008). www.americanheart.org/downloadable/heart/ 1200082005246HS- Stats%202008.final.pdf
3. Fisher M: Stroke and TIA: Epidemiology, risk factors, and the need for early intervention. Am J Manag Care. (2008) 14(6 Suppl 2):S204-S211.
4. Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. Lancet. (2008) 371(9624):1612-1623.
5. Bejot Y, Benatru I, Rouaud O, Fromont A, Besancenot JP, Moreau T, Giroud M: Epidemiology of stroke in Europe: Geographic and environmental differences. J Neurol Sci. (2007) 262(1-2):85-88.
6. Feigin VL, Lawes CM, Bennett DA, Anderson CS: Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancett Neurol. (2003) 2(1):43-53.
7. Lavados PM, Hennis AJ, Fernandes JG, Medina MT, Legetic B, Hoppe A, Sacks C, Jadue L, Salinas R: Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancett Neurol. (2007) 6(4): 362-372.
8. Lo EH: A new penumbra: Transitioning from injury into repair after stroke. Nat Med. (2008) 14(5):497-500.
9. van der Worp HB, van Gijn J: Clinical practice. Acute ischemic stroke. N Engl J Med. (2007) 357(6):572-579.
10. Mehta SL, Manhas N, Raghubir R: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Res. (2007) 54(1):34-66.
11. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. (1999) 22(9):391-397.
12. Halliwell B: Oxidative stress and neurodegeneration: Where are we now?J Neurochem. (2006) 97(6):1634-1658.
13. Stroke Therapy Academic Industry Roundtable: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. (1999) 30(12):2752-2758.
14. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. (2007)357(6):562-571.
15. Dirnagl U: Inflammation in stroke: The good, the bad, and the unknown. Ernst Sobering Res Found Workshop. (2004) (47):87-99.
16. Barone FC, Feuerstein GZ: Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab. (1999) 19(8):819-834.
17. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS: Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol. (2005) 289(2):H558-H568.
18. Candelario-Jalil E, Yang Y, Rosenberg GA: Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. (2009) 158(3):983-994.
19. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA: Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. (2007) 27(4):697-709.
20. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S: Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol. (2004) 56(4):468-477.
21. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, Jahan R, Vinuela F, Kang DW, Warach S: Thrombolytic toxicity: Blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis. (2008) 25(4):338-343.
22. Cunningham LA, Wetzel M, Rosenberg GA: Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia. (2005) 50(4):329-339.
23. Phillis JW, Horrocks LA, Farooqui AA: Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res Res. (2006)52(2):201-243.
24. Candelario-Jalil E, Fiebich BL: Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des. (2008) 14(14):1401-1418.
25. Muralikrishna AR, Hatcher JF: Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med. (2006) 40(3):376-387.
26. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME: Reduced susceptibility to ischemic brain injury and N-methyl-D- aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. (2001) 98(3):1294-1299.
27. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL: Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem. (2007) 100(4):1108-1120.
28. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL: Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res. (2004) 1007(1-2):98-108.
29. Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. (2006) 5(1):75-86.
30. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: Downstream effectors of COX-2 neurotoxicity. Nat Med. (2006) 12(2):225-229. Demonstrates for the first time that activation of the prostanoid receptor EP1 mediates the detrimental effects of COX-2-derived prostaglandin E2 formation during ischemia, and identified the EP1 receptor as a new molecular target in ischemic stroke.
31. Abe T, Kunz A, Shimamura M, Zhou P, Anrather J, Iadecola C: The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab. (2009)29(1):66-72. Demonstrates the potential of targeting the EP1 receptor to confer protection in stroke. Methodologically, this study is a good example of how preclinical stroke research should be conducted.
32. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ: Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000) 10(1):95-112.
33. Collino M, Patel NS, Thiemermann C: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis. (2008) 2(3):179-197.
34. Culman J, Zhao Y, Gohlke P, Herdegen T: PPAR-y: Therapeutic target for ischemic stroke. Trends Pharmacol Sci. (2007) 28(5):244-249.
35. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez- Lopez D, Pradillo JM, Caso JR, Vivancos J, Nombela F, Serena J, Llzasoaln I et al. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARγ- dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci. (2009) 29(12):3875-3884.
36. NINDS: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. (1995)333(24):1581-1587.
37. Sumii T, Lo EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. (2002) 33(3):831-836.
38. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J: MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. (2008) 39(4):1121-1126.
39. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J: Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. (2006) 37(6):1399-1406.
40. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. (2003) 107(4):598-603.
41. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A: The proteolytic activity of tissue- plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. (2001) 7(1):59-64.
42. Shuaib A, Hussain MS: The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol. (2008) 59(1-2):4-14.
43. Pfefferkorn T, Rosenberg GA: Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. (2003) 34(8):2025-2030.
44. Aoki T, Sumii T, Mori T, Wang X, Lo EH: Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke. (2002) 33(11):2711-2717.
45. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG: Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocyclinein vivoandin vitro.Stroke. (2006) 37(4):1087- 1093.
46. Kaur C, Ling EA: Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res. (2008) 5(1):71-81.
47. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH:Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. (2008) 39(12):3372-3377. Using a clinically relevant animal model of embolic focal ischemia, this study demonstrated that combination therapy with minocycline may extend the tPA treatment time window in ischemic stroke.
48. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M: Minocycline treatment in acute stroke: An open-label, evaluator-blinded study. Neurology. (2007) 69(14):1404-1410.
49. Wieloch T, Nikolich K: Mechanisms of neural plasticity following brain injury. Curr Opin Neurobiol. (2006) 16(3):258-264.
50. Cramer SC: Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. (2008) 63(5):549-560.
51. Cramer SC: Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann Neurol. (2008) 63(3):272-287.
52. Perez de la Ossa N, Davalos A: Neuroprotection in cerebral infarction: The opportunity of new studies. Cerebrovasc Dis. (2007) 24(Suppl 1):153-156.
53. Roitbak T, Li L, Cunningham LA: Neural stem/progenitor cells promote endothelial cell morphogenesis and protect endothelial cells against ischemia via HIF-1α-regulated VEGF signaling. J Cereb Blood Flow Metab. (2008) 28(9):1530-1542.
54. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA:VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. (2003) 111(12):1843-1851.
55. Kokaia Z, Thored P, Arvidsson A, Lindvall O: Regulation of stroke- induced neurogenesis in adult brain - Recent scientific progress. Cereb Cortex. (2006) 16(Suppl 1):i162-167.
56. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger M, Schwab ME, Vivien D et al. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. (2008) 25(3):268-278.
57. Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O:Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke. (2007) 38(11):3032-3039.
58. Thored P, Arvidsson A, Cacci E, Ahlenius H, Kallur T, Darsalia V, Ekdahl CT, Kokaia Z, Lindvall O: Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cell. (2006) 24(3):739-747.
59. Zhang Z, Chopp M: Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med. (2002) 12(2):62-66.
60. Hayashi T, Abe K, Itoyama Y: Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab. (1998) 18(8):887-895.
61. Minnerup J, Schabitz WR: Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics. (2009) 6(1):43-52.
62. Ginsberg MD: Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology. (2008) 55(3):363-389.
63. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA: A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. (1997) 49(3):671- 678.
64. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. (1999) 30(12):2592-2597.
65. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE: A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. (2001) 57(9):1595-1602.
66. Minnerup J, Heidrich J, Wellmann J, Rogalewski A, Schneider A, Schabitz WR: Meta-analysis of the efficacy of granulocyte- colony stimulating factor in animal models of focal cerebral ischemia. Stroke. (2008) 39(6):1855-1861.
67. SYGNIS-Pharma AG: SYGNIS starts Phase II efficacy trial of AX200 for the treatment of acute ischemic stroke. Press Release. (2009):May 5.
68. Park HP, Nimmagadda A, DeFazio RA, Busto R, Prado R, Ginsberg MD: Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: A two-photon laser-scanning microscopy study. Stroke. (2008) 39(5):1556-1562.
69. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. (2003) 53(6):743-751.
70. Fuentes B, Martinez-Sanchez P, Diez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis. (2009) 27(Suppl 1):126-133.
71. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, Ayata C: Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain. (2007) 130(Pt 6):1631-1642.
72. Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ: Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab. (2006) 26(10):1274-1284.
73. Liu W, Sood R, Chen Q, Sakoglu U, Hendren J, Cetin O, Miyake M, Liu KJ: Normobaric hyperoxia inhibits NADPH oxidase- mediated matrix metalloproteinase-9 induction in cerebral microvessels in experimental stroke. J Neurochem. (2008) 107(5):1196-1205.
74. Singhal AB: A review of oxygen therapy in ischemic stroke. Neurol Res. (2007) 29(2):173-183.
75. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. (1999) 19(6):624-633.
76. Rosenberg GA, Estrada EY, Dencoff JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. (1998) 29(10):2189-2195.
77. Lee SR, Kim HY, Rogowska J, Zhao BQ, Bhide P, Parent JM, Lo EH: Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J Neurosci. (2006) 26(13):3491-3495. Describes the dual roles of MMPs in ischemia. The researchers demonstrate that delayed administration of MMP inhibitors could impair the protective endogenous mechanisms associated with the neurogenic response to stroke.
78. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH: Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. (2006) 12(4):441-445.
79. Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang Y, Chopp M: Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci. (2006) 26(22):5996-6003.
80. Sood RR, Taheri S, Candelario-Jalil E, Estrada EY, Rosenberg GA: Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab. (2008) 28(2):431-438.
81. Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. (2008) 8(1):82-89.
82. Sasaki T, Kitagawa K, Sugiura S, Omura-Matsuoka E, Tanaka S, Yagita Y, Okano H, Matsumoto M, Hori M: Implication of cyclooxygenase-2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia. J Neurosci Res. (2003) 72(4):461-471.
83. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH: Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations. Stroke. (2009) 40(6):2244-2250.
84. Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A: The development of stroke therapeutics: Promising mechanisms and translational challenges. Neuropharmacology. (2009) 56(2):329-341. Evaluates important past and current approaches to drug development in stroke, emphasizing principles of translational research.
85. FAST-MAG Pilot Study:UCLA Stroke Center, Los Angeles, CA, USA (2008). www.strokecenter.org/trials/trialDetail.aspx?tid=198
86. STEMS2 - Stem cell trial of recovery enhanceMent after stroke 2:University of Nottingham, Nottingham, UK (2009). www.strokecenter,org/ trials/trialDetail,aspx?tid=942&searoh- string=G-CSF
87. Aronowski J, Strong R, Shirzadi A, Grotta JC: Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: Preclinical experience. Stroke. (2003) 34(5):1246-1251.
88. Neu 200: Neurotech Pharmaceutical Co Ltd, Gyeonggi-Do, South Korea (2002). www.neurotech-pharma.com/English/02-rnd/pipe-01.asp
89. ENACT Trial:University of Calgary, Alberta, Canada (2009). www.strokecenter,org/trials/trialDetail,aspx?tid=889&search-string=NA-. string=NA-1